60 Degrees Pharmaceuticals (SXTP) Depreciation & Amortization (CF) (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Depreciation & Amortization (CF) of $16700.0 for Q1 2026, up 149.48% year-over-year from $6694.0 in Q1 2025, and up 10.09% quarter-over-quarter from $15169.0 in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Depreciation & Amortization (CF) for 5 consecutive years, with $16700.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 149.48% year-over-year to $16700.0; the TTM figure through Mar 2026 stood at $53330.0 (up 196.06% YoY), while the FY2025 annual figure was $43324.0, up 269.47% from the prior year.
- Depreciation & Amortization (CF) advanced to $16700.0 in Q1 2026 per SXTP's latest filing, from $15169.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $16700.0 in Q1 2026 and bottomed at $407.0 in Q1 2024.
- Historically, Depreciation & Amortization (CF) has averaged $7100.9 across 5 years, with a median of $6901.0 in 2022.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) slumped 94.1% — and 2025, when it soared 1544.72%.
- 60 Degrees Pharmaceuticals' Depreciation & Amortization (CF) stood at $6901.0 in 2022, then tumbled by 72.83% to $1875.0 in 2023, then surged by 190.61% to $5449.0 in 2024, then surged by 178.38% to $15169.0 in 2025, then climbed by 10.09% to $16700.0 in 2026.
- Business Quant data shows SXTP's Depreciation & Amortization (CF) at $16700.0 in Q1 2026, $15169.0 in Q4 2025, and $12225.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | 16,950.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16,700.00 |
| Mar 31, 2026 | 16,700.00 |
| Dec 31, 2025 | 15,169.00 |
| Dec 31, 2025 | 15,169.00 |
| Sep 30, 2025 | 12,225.00 |
| Sep 30, 2025 | 12,225.00 |
| Jun 30, 2025 | 9,236.00 |
| Jun 30, 2025 | 9,236.00 |
| Mar 31, 2025 | 6,694.00 |
| Mar 31, 2025 | 6,694.00 |
| Dec 31, 2024 | 5,449.00 |
| Dec 31, 2024 | 5,449.00 |
| Sep 30, 2024 | 4,334.00 |
| Sep 30, 2024 | 4,334.00 |
| Jun 30, 2024 | 1,536.00 |
| Jun 30, 2024 | 1,536.00 |
| Mar 31, 2024 | 407.00 |
| Mar 31, 2024 | 407.00 |
| Dec 31, 2023 | 1,875.00 |
| Dec 31, 2023 | 1,875.00 |